Navigation Links
Pharmasset to Present at Lazard Capital Markets Healthcare Conference

PRINCETON, N.J., Nov. 9 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces management will present at the Sixth Annual Lazard Capital Markets Healthcare Conference. The conference will be held at the St Regis Hotel in New York City (November 17-19, 2009).

Schaefer Price, Pharmasset's President and Chief Executive Officer, will provide an overview of the company on Wednesday, November 18, 2009 at 3:45 PM (ET).

To access a simultaneous webcast of Mr. Price's overview via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at . Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.

A replay of the webcast will be available on Pharmasset's website for thirty days following the conference. The investor presentation will be available for download in PDF format immediately following each presentation in the "Events & Presentations" section of the Investor Center on Pharmasset's website at .

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(TM) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase thus inhibiting viral replication. We currently have three clinical-stage product candidates. RG7128, a nucleoside analog for chronic HCV infections, is in a Phase 2b clinical trial in combination with Pegasys® plus Copegus® and is also in INFORM studies, the first series of studies designed to assess the potential of combinations of small molecules without Pegasys® and Copegus® to treat chronic HCV. These clinical studies are being conducted through a strategic collaboration with Roche. Our other clinical stage candidates include PSI-7851, an unpartnered, next generation HCV nucleotide analog, has completed initial Phase 1 clinical studies which provided supportive safety and efficacy data to initiate a Phase 2a trial in 1Q 2010 and Racivir, for the treatment of HIV, which has completed a Phase 2 clinical trial. We have also recently announced the nomination of two purine nucleotide analogs, PSI-938 and PSI-879, for preclinical development.

Pegasys(®) and Copegus(® )are registered trademarks of Roche.

    Richard E. T. Smith, Ph.D.
    VP, Investor Relations and Corporate Communications
    Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including, without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2008 and our Quarterly Report on Form 10-Q for the period ended June 30, 2009 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.

SOURCE Pharmasset, Inc.

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
2. Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences
3. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
4. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
5. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
6. Pharmasset Reports Fiscal Year End 2008 Financial Results
7. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
8. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
9. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
10. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
11. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
Post Your Comments:
(Date:11/30/2015)... Elbit Imaging Ltd. (TASE, NASDAQ: ... that it was informed by InSightec Ltd. ("InSightec"), that the ... approved its Exablate Neuro system to treat movement, pain ... --> Insightec,s Exablate Neuro platform is transforming medicine ... technologies: Focused Ultrasound, which is used to lesion the ...
(Date:11/29/2015)... Health Cloud 1 was unveiled today at the 101 ... (RSNA) meeting in Chicago . ... and its applications will connect radiologists and clinicians to speed, ... both inside and outside the hospital setting. ... digital industrial leader, we are betting big on the GE ...
(Date:11/27/2015)... , Niederlande, November 27, 2015 ... fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   --> ... Bremachlorin-Therapie bei fortgeschrittenem Krebs.   --> ... Bremachlorin-Therapie bei fortgeschrittenem Krebs.   Clinical ... --> Clinical Cancer Research vom ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... , ... GKhair & Tibolli team members and artists were excited and proud ... 8th and 9th at the Puerto Rico Convention Center, San Juan Puerto Rico. The ... of the line fashion journalists. The San Juan Beauty Show carries immense credibility among ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... professionals worldwide today released the results of a survey of educational needs for ... Africa found a growing global demand for high quality online and face-to-face education ...
(Date:11/30/2015)... ... 2015 , ... Workstation solutions provider , HealthPostures, announces ... located throughout the United States, is OneStop Ergonomics. The addition allows HealthPostures to ... government workers and organizational leaders that are introduced to innovative methods that could ...
(Date:11/30/2015)... , ... November 30, 2015 , ... Bayco Products, Inc today announced the introduction of ... Available in a choice of three different colors; red ( NSP-1632 ), yellow ( NSP-1634 ... up to 18 hours in constant-on mode, or 27 hours in blinking strobe mode using ...
(Date:11/29/2015)... , ... November 29, 2015 ... ... accredited by the American Institute of Ultrasound in Medicine! , AIUM ultrasound ... demonstrate that they meet or exceed nationally recognized standards in the performance ...
Breaking Medicine News(10 mins):